04.12.2017 • NewsElaine BurridgeNSCLCcancer

AstraZeneca and G1 Therapeutics in Lung Cancer Pact

(c) anyaivanova/Shutterstock
(c) anyaivanova/Shutterstock

AstraZeneca and GI Therapeutics, a US clinical-stage oncology company, are collaborating to test a new combination therapy for lung cancer. The parties will evaluate AstraZeneca’s Tagrisso with G1’s oral CDK4/6 inhibitor G1T38 to treat epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

Under terms of the agreement, G1 will sponsor and conduct a Phase 1b/2 study together with the Anglo-Swedish drugmaker, in patients with NSCLC who have experienced disease progression on first-line EGFR inhibitors and harbor the EGFR T790M mutation. G1 plans to start the trial in the first quarter of 2018.

 “CDK4/6 inhibitors can enhance the efficacy of targeted therapies, and G1T38 has already shown encouraging preclinical and initial clinical data that support a potential best-in-class profile. The addition of G1T38 to Tagrisso in EGFR mutation-positive NSCLC has the potential to prolong the time to disease progression by overcoming resistance mechanisms,” said Mark Velleca, CEO of G1 Therapeutics.

Tagrisso is currently used as a second-line treatment for patients with EGFR-T790M mutation-positive advanced NSCLC. The European Medicines Agency is now reviewing AstraZeneca’s application to market Tagrisso for the first-line treatment of patients with this form of lung cancer.

According to AstraZeneca, roughly 10-15% of lung-cancer patients in Europe and the US have NSCLC with EGFR mutations.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.